

Natural Killer (NK) Cell Therapeutics Market to Reach USD 5.09 Billion by 2026 : Allied Market Research

NK Cell Therapeutics market was projected at \$1.40 billion in 2018 and is expected to hit \$5.09 billion by 2026, registering a CAGR of 17.4%

PORTLAND, OR, UNITED STATES, June 8, 2023 /EINPresswire.com/ -- The global [NK Cell Therapeutics market](#) was projected at \$1.40 billion in 2018 and is expected to hit \$5.09 billion by 2026, registering a CAGR of 17.4% during 2019–2026.



Rise in use of NK cells for the treatment of infections & liver diseases, surge in awareness among the population regarding various immunotherapies, and increase in R&D for the development of bi-specific antibody for engaging NK cells to eliminate tumor cells propel the growth of the global NK cell therapeutics market. On the other hand, lack of specificity & poor in-vivo survival of the cells, higher costs associated with the therapies, and their adverse side effects restrain the growth of the market to some extent. However, significant surge in R&D activities toward development of immunotherapy in developing economies is anticipated to create lucrative opportunities in the near future.

Request a sample report : <https://www.alliedmarketresearch.com/request-sample/2132>

Report ID: AMR-2132 | Report Title: Global Natural Killer Cells Therapeutics Market | Report Type: Market Research Report | Report Size: 100 Pages | Report Price: \$1,500

Based on therapeutics, the NK cell-directed antibodies segment accounted for nearly three-fifths of the total market share in 2018 and is anticipated to rule the roost during the estimated period. Increase in usage of monoclonal antibodies for the treatment of various diseases and its easy availability spur the growth. At the same time, the NK cell therapies segment would grow at the fastest CAGR of 17.6% till 2026. Extensive research in developing NK cell therapeutics to treat cancer is the major factor driving the growth.

□□□ □□□□□□ □□□□□□□□ □□□ □□□□□□ □□□□□□ □□ □□□□-

Based on application, the cancer segment contributed to more than three-fourths of the total market revenue in 2018 and is expected to dominate through 2019–2026. This is attributed to significant increase in the prevalence of cancer in this region. The gastrointestinal diseases segment, on the other hand, is projected to grow at the fastest CAGR of 19.3% during the forecast period. This is attributed to the rising growth in geriatric population, and improvement in healthcare facilities in the province.

□□□□□□ □□□□□□□ □□□□□□ (□□□ □□□□□ □□□ □□□□ □□□□□□□□□□, □□□□□□□, □□□□□□□, □□□□ □□□□□□□□) @ <https://www.alliedmarketresearch.com/checkout-final/0bb390aeeaa38cc4eae548152f3d6176>

□□□□□ □□□□□□□ □□ □□ □□□□□□□□ □□ □□□□-

Based on geography, North America held the major share in 2018, accounting for nearly half of the total market. Surge in the incidence of cancer in the region has driven the growth. At the same time, the Asia-Pacific region is predicted to showcase the fastest CAGR of 19.5% throughout the study period.

□□□□□□□ □□□□□□ □□□□□ □□□□□□□□□□□□□ □□□□□□ □□□ □□□□□□□□:

The key market players analyzed in the report include Affimed N.V., Altor BioScience Corporation, Chipscreen Biosciences, Ltd., NKT Therapeutics, Inc., Innate Pharma S.A., Sorrento Therapeutics Inc., NantKwest Inc., Bristol-Myers Squibb, Takeda Pharmaceutical Company Limited, and others. Incorporating a number of high-end strategies including expansions, mergers & acquisitions, partnerships, joint ventures, collaborations, and others, these market players have become able to heighten their stand in the industry.

□□□ □□□□□□□□ □□□□□□□ □□: <https://www.alliedmarketresearch.com/purchase-enquiry/2132>

□□□□□□□□ □□□□□□□ □□ □□□□□□□□□□ □□□□□□□□:

Central Lab Market Size: <https://www.alliedmarketresearch.com/central-lab-market-A15406>

Gene Synthesis Market Share: <https://www.alliedmarketresearch.com/gene-synthesis-market-A39015>

□□□□□□□□:

David Correa
5933 NE Win Sivers Drive
205, Portland, OR 97220

United States

USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022

UK: +44-845-528-1300

Hong Kong: +852-301-84916

India (Pune): +91-20-66346060

Fax: +1(855)550-5975

help@alliedmarketresearch.com

□□□□ □□:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

David Correa

Allied Analytics LLP

+ 1-800-792-5285

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/638343035>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.